[A17-36] Baricitinib (rheumatoid arthritis) - Addendum to commission A17-14

Last updated 21.09.2017

Project no.:
A17-36

Commission:
Commission awarded on 08.08.2017 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Muscles, bones and joints

Indication/Intervention:

Moderate to severe rheumatoid arthritis in adult patients who have responded inadequately to pretreatment

Result of dossier assessment:

Neither advantage nor disadvantage proven from the consideration of the total study population of the JADV study for research questions 2 and 3 of dossier assessment A17-14

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Current document

Federal Joint Committee (G-BA)

A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.